Sars-CoV2 Antibody Responses in Patients with Hematological Malignancies Following Anti-CD20 Therapy

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with increased mortality in patients with hematological malignancies, with increase rates between 33-37%. Vaccination against SARS-CoV-2 have shown efficacy decreasing infection rates, with efficacy rates of 50-95%. However, the immunogenicity in immune-compromised patients, particularly those with prior exposure to anti-CD20 antibodies and duration of protective immunity, remains unknown. The current guidelines recommend vaccination for all patients receiving cancer therapy with a 3 months delay following hematological stem cell transplant and CAR-T cell therapy.